Valerio Therapeutics (LTS:0NWK) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0NWK Valerio Therapeutics LTS:0NWK
32 GF Score
Price €0.77
GF Value €0.07
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Valerio Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0NWK
32GF Score
Valerio Therapeutics LTS:0NWK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valerio Therapeutics (LTS:0NWK) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.77 is trading 1000% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for LTS:0NWK:

  • FFO:
  • GF Value™: €0.07 vs. price of €0.77 (1000% above fair value)
  • GF Score™: 32/100 with 9 warning signs

No single metric tells the full story. See the LTS:0NWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Valerio Therapeutics Business Description

Other Exchanges ALVIO:FranceC4X:Germany
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
32GF Score

Get the complete analysis for LTS:0NWK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€0.07
GF Value